

REMARKS

Pursuant to 37 C.F.R. § 1.121, the marked-up version of the above amendments is appended hereto as Appendix A.


The above amendments are made solely to comply with the requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequences Disclosures, 37 CFR §§ 1.821-1.825.

Date: September 18, 2001



Edwin V. Merkel
Registration No. 40,087

Nixon Peabody LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (716) 263-1128
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C 20231 on the date below.	
9/18/01	
Date	Jo Ann Whalen

VERSION WITH MARKINGS TO SHOW CHANGES MADE TO U.S. PATENT
APPLICATION SERIAL NO. 09/576,724



Page 1 of 3

RECEIVED

SEP 24 2001

TECH CENTER 1600/2900

In reference to the amendments made herein to the Claims and the Specification, additions appear as underlined text, while deletions appear in brackets, as indicated below:

In the Claims:

3. (Twice Amended) The antibody according to claim 1, wherein the protein sequence recognized by the antibody is

(SEQ. ID. No. 1) -Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-
or a part thereof.

10. (Twice Amended) A method of producing an antibody according to claim 1 comprising the step of immunizing an animal with an amount of a peptide having the amino acid sequence

(SEQ. ID. No. 1) -Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-
or

(SEQ. ID. No. 2) -Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-
or a variant thereof, obtained by substituting, deleting or adding one or more amino acids with the proviso that the three dimensional conformation is essentially retained, sufficient to elicit an immune response.

17. (Amended) A peptide having the amino acid sequence
(SEQ. ID. No. 1) -Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-
or a sequence derived therefrom by substituting one or more amino acids with the proviso that the three conformational characteristics of said peptide is essentially maintained.

18. (Amended) A peptide according to claim 17, wherein the peptide is
(SEQ. ID. No. 2) -Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

**VERSION WITH MARKINGS TO SHOW CHANGES MADE TO U.S. PATENT
APPLICATION SERIAL NO. 09/576,724**

Page 2 of 3

In the Specification:

The paragraph at Page 6, lines 5-7, has been amended as follows:

Fig. 7 shows the results of a Dot Blot experiment, wherein various samples of normal brain tissues are exposed to the antibody CNCM-I-2476. As a control the peptide of [Seq.]SEQ. ID. No. 1 [2] and the conjugate of said peptide and KLH was used.

The paragraph at Page 6, line 22, has been amended as follows:

(SEQ. ID. No. 1) Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

The paragraph at Page 6, line 25, has been amended as follows:

(SEQ. ID. No. 2) Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

The paragraph at Page 6, lines 27-29, has been amended as follows:

The following sequence (SEQ. ID. No. 3) [Seq. ID No 1] shows a part of the C-terminal region of the amino acid sequence of the bovine prion polypeptide that is from amino acid no. 180 to no. 219 as identified in the present invention.

The paragraph at Page 9, line 12, has been amended as follows:

(SEQ. ID. No. 1) -Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

The paragraph at Page 9, line 16, has been amended as follows:

(SEQ. ID. No. 2) -Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

The paragraph at Page 10, line 6, has been amended as follows:

(SEQ. ID. No. 2) -Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

The paragraph at Page 10, line 12, has been amended as follows:

APPENDIX A

**VERSION WITH MARKINGS TO SHOW CHANGES MADE TO U.S. PATENT
APPLICATION SERIAL NO. 09/576,724**

Page 3 of 3

(SEQ. ID. No. 1) -Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-

The paragraph at Page 11, line 16, has been amended as follows:

(SEQ. ID. No. 2) Cys-Ile-Thr-Gln-Tyr-Gln-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr

The paragraph at Page 11, line 20, has been amended as follows:

(SEQ. ID. No. 1) Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr

The paragraph at Page 12, line 11, has been amended as follows:

(SEQ. ID. No. 1) H-Cys-Ile-Thr-Gln-Tyr-Glu-Arg-Glu-Ser-Gln-Ala-Tyr-Tyr-OH